Human Properdin Protein, His Tag

Cat. No. / Size
Price
Availability
Qty
PRN-H52H3-100ug
$360.00
In Stock - Delivery in 1-2 business days
PRN-H52H3-1mg (200ug X 5)
$2,615.00
In Stock - Delivery in 1-2 business days
PRN-H52H3
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

Properdin, Complement factor P, CFP, PFC

Source

Human Properdin, His Tag (PRN-H52H3) is expressed from human 293 cells (HEK293). It contains AA Asp 28 - Leu 469 (Accession # P27918-1).

Predicted N-terminus: Asp 28

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 50.7 kDa. The protein migrates as 55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

Properdin is also known as Complement factor P, CFP, PFC, a positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes. Properdin is produced by many different leukocyte subsets and circulates as cyclic oligomers of monomeric subunits. Properdin on platelet/granulocyte aggregates(PGA) formation are tightly regulated by Factor H, properdin enhances PGA formation via increased production of C5a, and that inhibition of properdin function has therapeutic potential to limit thromboinflammation in diseases characterized by increased PGA formation.